Study: Ebola Vaccine May Fall Short

One of the Ebola vaccines about to enter testing in Liberia may not be as potent as researchers had hoped, according to a new study, raising questions about how well it will prevent infection. The vaccine, developed by GlaxoSmithKline, is one of two in a large-scale clinical trial expected to begin in the next two weeks. Merck produced the other vaccine. Earlier studies had found that one dose of the GSK vaccine would protect monkeys from Ebola. However, in the study published in...

© La Voix de l'Amérique - mercredi 28 janvier 2015